KCM
CRL icon

Kingdon Capital Management’s Charles River Laboratories CRL Stock Holding History

Kingdon Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-75,700
Closed -$14M – 77
2024
Q4 		$14M Buy
75,700
+1,600
+2% +$308K 1.99% 16
2024
Q3 		$14.6M Buy
74,100
+4,300
+6% +$894K 1.62% 17
2024
Q2 		$14.4M Buy
+69,800
New +$15.8M 1.55% 22
2022
Q3 		– Sell
-38,365
Closed -$8.21M – 70
2022
Q2 		$8.21M Sell
38,365
-11,835
-24% -$2.89M 1.39% 21
2022
Q1 		$14.3M Buy
+50,200
New +$15.5M 1.49% 19

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Kingdon Capital Management's CRL Position: Q1 2025 in Review

Kingdon Capital Management sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 75,700 shares — an estimated $14M sold.

Kingdon Capital Management first reported a position in CRL in Q1 2022 and held it in 5 quarters. The position peaked at $14.6M in Q3 2024. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Kingdon Capital Management reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • Kingdon Capital Management sold 75,700 Charles River Laboratories shares in Q1 2025, an estimated $14M.
  • Kingdon Capital Management first reported a position in Charles River Laboratories in Q1 2022 and held it in 5 quarters.
  • Kingdon Capital Management's Charles River Laboratories position peaked at $14.6M in Q3 2024.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Kingdon Capital Management's 13F filing for Q1 2025, filed 15 May 2025.